Who Exports Primaquine from India — 116 Suppliers Behind a $1.7M Market

Hyderabad, often referred to as the "Bulk Drug Capital of India," is a central hub for the production of Active Pharmaceutical Ingredients (APIs). The city hosts over 800 pharmaceutical companies, including major players such as Dr. Reddy’s Laboratories, Aurobindo Pharma, and Divi’s Laboratories. The presence of Genome Valley, India's first biotech cluster, further enhances Hyderabad's capabilities in pharmaceutical research and development. This concentration of expertise and infrastructure makes Hyderabad a key player in the production of APIs essential for medications like Primaquine.

The Ahmedabad-Vadodara corridor in Gujarat is renowned for its focus on pharmaceutical formulations. Gujarat contributes nearly 28% of India's pharmaceutical production, with a strong emphasis on finished dosage forms. The region is home to leading companies such as Zydus Cadila, Intas Pharmaceuticals, and Torrent Pharmaceuticals. The robust infrastructure, including well-developed ports and transportation networks, facilitates efficient manufacturing and distribution of pharmaceutical products, including Primaquine tablets.

The Mumbai-Thane-Raigad belt in Maharashtra serves as a critical export gateway for India's pharmaceutical industry. This region hosts numerous pharmaceutical companies and benefits from proximity to major ports, enabling efficient export operations. The well-established logistics and regulatory framework in this area support the global distribution of pharmaceuticals, including antimalarial drugs like Primaquine.

Baddi and Nalagarh in Himachal Pradesh have emerged as significant pharmaceutical manufacturing zones, largely due to favorable tax incentives and government policies. Baddi, in particular, is recognized as India's largest pharmaceutical manufacturing hub by volume, housing over 1,000 pharmaceutical units. The region's strategic location and supportive infrastructure have attracted numerous pharmaceutical companies, contributing to its prominence in the industry.

• Diversify Supplier Base: To mitigate risks associated with supply chain disruptions, consider sourcing Primaquine from multiple manufacturers across different pharmaceutical clusters in India.

• Evaluate Supplier Capabilities: Assess the manufacturing capabilities and quality standards of potential suppliers, focusing on their experience in producing antimalarial medications.

• Leverage Export Hubs: Utilize the Mumbai-Thane-Raigad region's export infrastructure to facilitate efficient international distribution of Primaquine.

• Monitor Regulatory Compliance: Ensure that selected suppliers comply with international regulatory standards and possess necessary certifications for the production and export of pharmaceuticals.